Recently discovered biomarkers may provide valuable new approaches to monitoring immunosuppressive drug therapy in organ transplant recipients — with the potential for individualized therapy to reduce organ rejection and minimize side effects
Recently discovered biomarkers may provide valuable new approaches to monitoring immunosuppressive drug therapy in organ transplant recipients — with the potential for individualized therapy to reduce organ rejection and minimize side effects